NasdaqGS:IDYABiotechs
IDEAYA Biosciences (IDYA): Revenue Forecast to Grow 28.3% Annually, Profit Still Elusive
IDEAYA Biosciences (IDYA) reported a 45.2% per year increase in losses over the past five years and is forecasted to remain unprofitable for at least the next three years. However, revenue is projected to grow at 28.3% per year, notably outpacing the US market average of 10.5%. With robust top-line growth but continuing net losses, the results reflect a company in high-growth mode with persistent profitability hurdles for investors to watch.
See our full analysis for IDEAYA Biosciences.
Next,...